Careers in Israel
Careers in USA
Board of Directors
Scientific Advisory Board
Johns Hopkins University
Annual and Quarterly Reports
Therapeutic product discovery
In the information age
The next wave in immuno-oncology
May 23, 2017
Compugen to Present at Two Upcoming Investor Conferences in June
May 09, 2017
Compugen Reports First Quarter 2017 Results
Our optimized process for predictive discovery of novel drug targets
Discovery & development of first-in-class monoclonal antibody therapeutics
CGEN-15029 is the internal designation for PVRIG, a novel B7/CD28-like immune checkpoint target candidate discovered by...
CGEN-15137 is the internal designation for TIGIT, an immune checkpoint in the B7/CD28 family which has recently gained broad...
CGEN-15001T is a novel B7/CD28-like immune checkpoint target candidate discovered by Compugen. CGEN-15001T is expressed in various subpopulations of immune cells...
CGEN-15022 is a novel B7/CD28-like immune checkpoint target candidate discovered by Compugen. CGEN-15022 is expressed in numerous types of epithelial cancers, such...
CGEN-15001 is our lead program for autoimmune diseases. It is a first-in-class therapeutic candidate of a novel inhibitory checkpoint pathway, with the potential to restore...
Jun 05, 2017
Compugen to Present at 2017 ASCO
May 09, 2017
Compugen First Quarter 2017 Conference Call Scheduled for Tuesday, May 9, 2017 at 10:00 AM ET
May 14, 2017
Compugen to Present at IMMUNOLOGY 2017
In August 2013, Compugen entered into a collaboration and license agreement with Bayer HealthCare ...
Click here for more info about partnering with Compugen